April 25th 2024
Study in JAMA: Antenatal corticosteroids don't impact neurodevelopment in late preterm children aged 6 years and up.
Earn CME Credits While Advancing Your Expertise in Internal Medicine
April 18-19, 2024
Register Now!
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Cases and Conversations™: Evidence-Based Approaches to Management of CKD in Your Patients with T2DM
September 25, 2024
Register Now!
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
3rd Annual International Congress on Pediatric Oncology
October 25, 2024
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Adolescents with ADHD Need Special Attention
October 29th 2007Adolescents with ADHD are different from other patients. Impulsiveness and inattention pose bigger problems than hyperactivity, which can translate into lower medication adherence and growing behavioral problems. And adolescent girls tend to exhibit more problems than boys in the same age range.
ADHD pharmacotherapy: Prescribe with safety in mind and monitor results with vigilance
June 14th 2007The keys to optimal use of psychostimulant and nonstimulant medications for attention deficit hyperactivity disorder are careful screening of patients, appropriate dosage regulation, and?most of all?close monitoring of both positive and adverse outcomes.
Brain's fear center smaller in most severely socially-impaired males with autism spectrum disorders
January 12th 2007Researchers funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) and National Institute on Child Health and Human Development (NICHD) have discovered that the brain's fear hub likely becomes abnormally small in the most severely socially-impaired males with autism spectrum disorder. New findings suggest that social fear in autism may initially trigger a hyperactive, abnormally enlarged amygdala, which eventually gives way to a toxic adaptation that kills amygdala cells and shrinks the structure, said Richard Davidson, Ph.D., and colleagues at the University of Wisconsin.
ADHD pharmacotherapy: Prescribe with safety in mind and monitor results with vigilance
December 1st 2006The keys to optimal use of psychostimulant and nonstimulant medications for attention deficit hyperactivity disorder are careful screening of patients, appropriate dosage regulation, and-most of all-close monitoring of both positive and adverse outcomes.
Transdermal delivery of methylphenidate passes a test of efficacy in ADHD
June 8th 2006New research reported at the annual meeting of the American Psychiatric Association in Toronto in May shows that Shire Pharmaceutical Group's methylphenidate transdermal system (Daytrana) appears a safe and well-tolerated alternative to OROS methylphenidate, and is equally efficacious.
ADHD study supports lower lead exposure limits
May 1st 2006A new study on potential interactions between genetic and environmental factors in ADHD suggests that current limits on lead exposure are too high. Lead exposure below the current limits allowed by Environmental Protection Agency regulations produced measurable impairment of executive functions, especially in boys, who have a specific variation in the DRD4 dopamine receptor gene.
Study: Ritalin effective in preschoolers with ADHD
October 10th 2005The longest and most complex study of methylphenidate (Ritalin) in preschool children shows that it can be safe and effective for some children in that age group who have attention deficit hyperactive disorder (ADHD), according to the study's lead author.
The question of the day: Is there an autism epidemic?
October 8th 2005The answer? We don't really know, according to Craig Newschaffer, PhD, associate professor at the Johns Hopkins School of Public Health. But fears of an autism epidemic have been overblown by the press and advocacy groups, said Dr. Newschaffer, speaking at the American Academy of Pediatrics National Conference and Exhibition today in Washington, D.C.
FDA extends indication for ADHD treatment formulation to adolescent years
October 5th 2005The US Food and Drug Administration (FDA) recently approved Adderall XR (an extended-release formulation of mixed salts of amphetamine) as a once-daily treatment for attention deficit hyperactivity disorder in adolescents 13 to 17 years old. That action bridges an "indication gap" between earlier approval of the product for patients 6 to 12 years old and for older (18 years) adolescents and adults.
Let's get discussion of what causes autism back on track!
September 1st 2005Lately, I've spent a lot of time talking about the alleged link between thimerosal in pediatric vaccines and autism. Most of you have been asked by parents whether immunizations pose a risk of autism as well, and some parents are so frightened by rumors, press reports, and information on the World Wide Web that they forgo immunizations for their children altogether.
Where we are, and how well we can succeed, at treating ADHD
December 1st 2003At pediatricians' disposal today are numerous formulations of approved medications for ADHD--traditional psychostimulants and newer agents. We also have developed an appreciation of the value of a multipronged approach to this chronic disorder.